Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires $50,200.00 in Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was bought at an average cost of $5.02 per share, for a total transaction of $50,200.00. Following the completion of the transaction, the chief executive officer now directly owns 2,285,731 shares in the company, valued at $11,474,369.62. This represents a 0.44 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Friday, February 28th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The stock was acquired at an average price of $4.76 per share, for a total transaction of $47,600.00.
• On Tuesday, February 25th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The stock was acquired at an average price of $4.46 per share, for a total transaction of $44,600.00.

Vanda Pharmaceuticals Trading Down 1.2 %

Shares of Vanda Pharmaceuticals stock traded down $0.06 during trading on Friday, hitting $4.85. 611,200 shares of the stock were exchanged, compared to its average volume of 675,564. The stock has a market capitalization of $282.83 million, a price-to-earnings ratio of -15.16 and a beta of 0.69. The company has a fifty day moving average price of $4.60 and a 200-day moving average price of $4.78. Vanda Pharmaceuticals Inc. has a 1-year low of $3.71 and a 1-year high of $6.75.

Remove Ads

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. The company had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. Equities research analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VNDA. Mackenzie Financial Corp acquired a new position in Vanda Pharmaceuticals in the 4th quarter valued at about $240,000. Squarepoint Ops LLC grew its stake in Vanda Pharmaceuticals by 186.4% in the 4th quarter. Squarepoint Ops LLC now owns 71,131 shares of the biopharmaceutical company's stock valued at $341,000 after buying an additional 46,293 shares during the last quarter. Two Sigma Advisers LP grew its stake in Vanda Pharmaceuticals by 11.2% in the 4th quarter. Two Sigma Advisers LP now owns 156,300 shares of the biopharmaceutical company's stock valued at $749,000 after buying an additional 15,700 shares during the last quarter. Two Sigma Investments LP grew its stake in Vanda Pharmaceuticals by 94.7% in the 4th quarter. Two Sigma Investments LP now owns 199,460 shares of the biopharmaceutical company's stock valued at $955,000 after buying an additional 97,017 shares during the last quarter. Finally, Stonepine Capital Management LLC acquired a new position in Vanda Pharmaceuticals in the 4th quarter valued at about $120,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

VNDA has been the topic of several recent research reports. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a "hold" rating on the stock. HC Wainwright lifted their price target on shares of Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.